French biotech firm sells shares above market price at rights issue

French gene therapy products developer Transgene has managed to raise €63m ($54m) from a rights offering on the Nouveau Marché despite the fact that its share price had plummeted to well below the offer price.

The issue was originally planned to raise €80m, but mustered €63m after the share price fell below the offer price the day after the terms for the rights issue were set.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump